Recursion Pharmaceuticals is trading 5.2% up today at $3.04 as the stock stages a modest rebound from recent weakness despite a lack of fresh company-specific catalysts.
- The move appears to be a technical bounce from an oversold setup in a volatile, beaten-down biotech name, notably outperforming sector peers which are trading lower today.
- Recent investor interest has focused on the company's clinical pipeline progress and continued backing from ARK Invest, though no new headlines or analyst calls were reported for July 21, 2026.